More exciting approval announcements for this week.
On May 15th, 2020, the Food and Drug Administration (FDA) approved the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) for treatment of advanced non-small cell lung cancer (NSCLC) with a PD-L1 level equal to or greater than 1% for patients that do not have EGFR or ALK mutations. The FDA based their approval on the results of the clinical trial CHECKMATE-227 which showed that patient receiving the combination of Opdivo (nivolumab) and Yervoy (ipilimumab) lived longer, were more likely to respond to treatment, and that the response lasted longer than patients receiving chemotherapy.
The approval of Opdivo (nivolumab) and Yervoy (ipilimumab) marks the first approval of combined immunotherapy treatment for NSCLC. This gives patients whose cancer does not have a targetable change a new avenue for treatment and more options than they have ever had.
If you have any questions about this approval or others, reach out to us at email@example.com or 1800-298-2436. We will also be providing links to read more about approvals in GO2's hot topics.
Sign up for our newsletter to get these updates at this webpage: secure.go2foundation.org/si...
Have a nice weekend, everyone!